52 research outputs found
The feasibility and acceptability of neuromuscular electrical stimulation to improve exercise performance in patients with advanced cancer: a pilot study
Evolução do status de performance, Ăndice de massa corpĂłrea e distância percorrida no teste de caminhada de seis minutos em pacientes com câncer de pulmĂŁo avançado submetidos Ă quimioterapia
Population-based reference values for the 1-min sit-to-stand test
OBJECTIVES: To determine reference values for the 1-min sit-to-stand (STS) test in an adult population.
METHODS: Cross-sectional study nested within a nationwide health promotion campaign in Switzerland. Adults performed the STS test and completed questions on demographics and health behavior.
RESULTS: 6,926 out of 7,753 (89.3 %) adults were able to complete the STS test. The median number of repetitions ranged from 50/min (25-75th percentile 41-57/min) in young men and 47/min (39-55/min) in young women aged 20-24Â years to 30/min (25-37/min) in older men and 27/min (22-30/min) in older women aged 75-79Â years.
CONCLUSIONS: The reference values support the interpretation of 1-min STS test performance and identification of subjects with decreased lower body muscular strength and endurance
“EXHALE”: exercise as a strategy for rehabilitation in advanced stage lung cancer patients: a randomized clinical trial comparing the effects of 12 weeks supervised exercise intervention versus usual care for advanced stage lung cancer patients
Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer
Benefits of home-based multidisciplinary exercise and supportive care in inoperable non-small cell lung cancer – protocol for a phase II randomised controlled trial
Impact of self-reported physical activity and health promotion behaviors on lung cancer survivorship
Development, effectiveness and cost-effectiveness of a new out-patient Breathlessness Support Service: study protocol of a phase III fast-track randomised controlled trial
Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?
- …